small molecule

MACRILEN

MACIMORELIN ACETATE

Loss of exclusivityApril 2028latest FDA-listed patent expiry
CompanyAEterna ZentarisView the full company profile on CliffBio

Drug detail

Brand nameMACRILEN
Active ingredientMACIMORELIN ACETATE
StrengthEQ 60MG BASE/POUCH
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
8192719*PEDApril 2028
8192719October 2027use U-2220

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MACRILEN patent cliff — loss of exclusivity April 2028 | CliffBio